{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:39:41Z","timestamp":1768808381714,"version":"3.49.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["ZD2021CY001"],"award-info":[{"award-number":["ZD2021CY001"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2021-2023 )-0103"],"award-info":[{"award-number":["2021-2023 )-0103"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82141203"],"award-info":[{"award-number":["82141203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.bioorg.2022.106264","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T02:23:41Z","timestamp":1667960621000},"page":"106264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses"],"prefix":"10.1016","volume":"130","author":[{"given":"Ruyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanglei","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanghao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengge","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyi","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weidong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangbo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.bioorg.2022.106264_b0005","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10229","key":"10.1016\/j.bioorg.2022.106264_b0010","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2022.106264_b0015","doi-asserted-by":"crossref","first-page":"110046","DOI":"10.1016\/j.pnpbp.2020.110046","article-title":"The SARS-CoV-2 and mental health: From biological mechanisms to social consequences","volume":"104","author":"Szcze\u015bniak","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bioorg.2022.106264_b0020","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12931-020-01479-w","article-title":"From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses","volume":"21","author":"Zhu","year":"2020","journal-title":"Respir. Res."},{"issue":"4","key":"10.1016\/j.bioorg.2022.106264_b0025","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/med.21783","article-title":"What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design","volume":"41","author":"Xiong","year":"2021","journal-title":"Med. Res. Rev."},{"issue":"12","key":"10.1016\/j.bioorg.2022.106264_b0030","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41576-021-00408-x","article-title":"The biological and clinical significance of emerging SARS-CoV-2 variants","volume":"22","author":"Tao","year":"2021","journal-title":"Nat. Rev. Genet."},{"issue":"4","key":"10.1016\/j.bioorg.2022.106264_b0035","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2022.106264_b0040","article-title":"Covid-19: UK becomes first country to authorise antiviral molnupiravir","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.bioorg.2022.106264_b0045","article-title":"Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk","volume":"375","author":"Mahase","year":"2021","journal-title":"MSD reports, Bmj"},{"key":"10.1016\/j.bioorg.2022.106264_b0050","article-title":"Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.bioorg.2022.106264_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2021.104941","article-title":"E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil","volume":"93","author":"Ferrareze","year":"2021","journal-title":"Infect. Genet. Evol."},{"issue":"7798","key":"10.1016\/j.bioorg.2022.106264_b0060","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"10224","key":"10.1016\/j.bioorg.2022.106264_b0065","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.bioorg.2022.106264_b0070","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J. Med. Chem."},{"issue":"7811","key":"10.1016\/j.bioorg.2022.106264_b0075","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"Pt 3","key":"10.1016\/j.bioorg.2022.106264_b0080","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1099\/0022-1317-83-3-595","article-title":"Conservation of substrate specificities among coronavirus main proteases","volume":"83","author":"Hegyi","year":"2002","journal-title":"J. Gen. Virol."},{"issue":"1","key":"10.1016\/j.bioorg.2022.106264_b0085","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1038\/s41467-020-16954-7","article-title":"Structural plasticity of SARS-CoV-2 3CL M(pro) active site cavity revealed by room temperature X-ray crystallography","volume":"11","author":"Kneller","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2022.106264_b0090","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science (New York N.Y.)"},{"issue":"6489","key":"10.1016\/j.bioorg.2022.106264_b0095","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.bioorg.2022.106264_b0100","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41401-020-0483-6","article-title":"Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients","volume":"41","author":"Su","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"issue":"19","key":"10.1016\/j.bioorg.2022.106264_b0105","doi-asserted-by":"crossref","first-page":"13343","DOI":"10.1021\/acs.jmedchem.2c01146","article-title":"Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity","volume":"65","author":"Gao","year":"2022","journal-title":"J. Med. Chem."},{"issue":"6575","key":"10.1016\/j.bioorg.2022.106264_b0110","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2022.106264_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114596","article-title":"A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals","volume":"240","author":"Alugubelli","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"9142","key":"10.1016\/j.bioorg.2022.106264_b0120","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(05)79824-X","article-title":"Fatal interaction between ritonavir and MDMA","volume":"352","author":"Henry","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bioorg.2022.106264_b0125","first-page":"20com02677","article-title":"Ritonavir\/Lopinavir and Its Potential Interactions With Psychiatric Medications: A COVID-19 Perspective","volume":"22","author":"Mansuri","year":"2020","journal-title":"Prim. Care Companion CNS Disord."},{"issue":"1","key":"10.1016\/j.bioorg.2022.106264_b0130","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41392-021-00763-5","article-title":"High-throughput screening and evaluation of repurposed drugs targeting the SARS-CoV-2 main protease","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"44","key":"10.1016\/j.bioorg.2022.106264_b0135","doi-asserted-by":"crossref","first-page":"23492","DOI":"10.1002\/anie.202107481","article-title":"Repurposing an Antiviral Drug against SARS-CoV-2 Main Protease","volume":"60","author":"Sarkar","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"2","key":"10.1016\/j.bioorg.2022.106264_b0140","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.apsb.2021.08.027","article-title":"Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors","volume":"12","author":"Gao","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2022.106264_b0145","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-981-16-0267-2_9","article-title":"Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses","volume":"1322","author":"Huang","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bioorg.2022.106264_b0150","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijbiomac.2021.04.129","article-title":"Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CL(pro)","volume":"183","author":"Wang","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioorg.2022.106264_b0155","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jgar.2020.01.002","article-title":"Identification of repositionable drugs with novel antimycotic activity by screening the Prestwick Chemical Library against emerging invasive moulds","volume":"21","author":"Yousfi","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"issue":"1","key":"10.1016\/j.bioorg.2022.106264_b0160","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41522-020-00181-5","article-title":"Impact of the repurposed drug thonzonium bromide on host oral-gut microbiomes","volume":"7","author":"Simon-Soro","year":"2021","journal-title":"npj Biofilms Microbiomes"},{"issue":"11","key":"10.1016\/j.bioorg.2022.106264_b0165","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1021\/acs.jproteome.0c00383","article-title":"In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins","volume":"19","author":"Maffucci","year":"2020","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bioorg.2022.106264_b0170","article-title":"Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern","volume":"3","author":"Murer","year":"2022","journal-title":"Curr. Res. Virol. Sci."},{"issue":"12","key":"10.1016\/j.bioorg.2022.106264_b0175","doi-asserted-by":"crossref","first-page":"e0144865","DOI":"10.1371\/journal.pone.0144865","article-title":"Critical Assessment of the Important Residues Involved in the Dimerization and Catalysis of MERS Coronavirus Main Protease","volume":"10","author":"Ho","year":"2015","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.bioorg.2022.106264_b0180","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1128\/JVI.79.11.7095-7103.2005","article-title":"Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro","volume":"79","author":"Chen","year":"2005","journal-title":"J. Virol."},{"issue":"24","key":"10.1016\/j.bioorg.2022.106264_b0185","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1016\/j.bmc.2006.09.014","article-title":"Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features","volume":"14","author":"Chen","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106264_b0190","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejmech.2018.03.004","article-title":"Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element","volume":"150","author":"Galasiti Kankanamalage","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2022.106264_b0195","doi-asserted-by":"crossref","first-page":"7646","DOI":"10.1074\/jbc.M807947200","article-title":"Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds","volume":"284","author":"Lee","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2022.106264_b0200","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1021\/acsptsci.0c00130","article-title":"Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors","volume":"3","author":"Ma","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"Pt 2","key":"10.1016\/j.bioorg.2022.106264_b0205","article-title":"Heparin interacts with the main protease of SARS-CoV-2 and inhibits its activity","volume":"267","author":"Li","year":"2022","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"issue":"21","key":"10.1016\/j.bioorg.2022.106264_b0210","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1021\/bi00745a020","article-title":"Quenching of fluorescence by oxygen. A probe for structural fluctuations in macromolecules","volume":"12","author":"Lakowicz","year":"1973","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2022.106264_b0215","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.ijbiomac.2020.07.235","article-title":"Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening","volume":"164","author":"Abian","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"issue":"3","key":"10.1016\/j.bioorg.2022.106264_b0220","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/protein\/5.3.191","article-title":"Quantitative analysis of protein far UV circular dichroism spectra by neural networks","volume":"5","author":"B\u00f6hm","year":"1992","journal-title":"Protein Eng."},{"issue":"6","key":"10.1016\/j.bioorg.2022.106264_b0225","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1038\/nprot.2006.202","article-title":"Using circular dichroism spectra to estimate protein secondary structure","volume":"1","author":"Greenfield","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bioorg.2022.106264_b0230","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.bios.2016.11.068","article-title":"A highly specific ratiometric two-photon fluorescent probe to detect dipeptidyl peptidase IV in plasma and living systems","volume":"90","author":"Zou","year":"2017","journal-title":"Biosens. Bioelectron."},{"issue":"6557","key":"10.1016\/j.bioorg.2022.106264_b0235","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1126\/science.abg5827","article-title":"Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2","volume":"373","author":"Drayman","year":"2021","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bioorg.2022.106264_b0240","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1021\/j100809a020","article-title":"Oxygen quenching of fluorescence in solution: an experimental study of the diffusion process","volume":"66","author":"Ware","year":"1962","journal-title":"J. Phys. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2022.106264_b0245","doi-asserted-by":"crossref","first-page":"10716","DOI":"10.1002\/anie.202016768","article-title":"Re(I) Tricarbonyl Complexes as Coordinate Covalent Inhibitors for the SARS-CoV-2 Main Cysteine Protease","volume":"60","author":"Karges","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"10236","key":"10.1016\/j.bioorg.2022.106264_b0250","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bioorg.2022.106264_b0255","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/s41467-021-22362-2","article-title":"Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors","volume":"12","author":"Iketani","year":"2021","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.bioorg.2022.106264_b0260","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S2213-2600(21)00377-5","article-title":"Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial","volume":"9","author":"Declercq","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"10321","key":"10.1016\/j.bioorg.2022.106264_b0265","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(21)02844-0","article-title":"Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum","volume":"399","author":"Dejnirattisai","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.bioorg.2022.106264_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104884","article-title":"Generation and characterization of Japanese encephalitis virus expressing GFP reporter gene for high throughput drug screening","volume":"182","author":"Zhang","year":"2020","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.bioorg.2022.106264_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emi.2017.23","article-title":"Identification of drug candidates that enhance pyrazinamide activity from a clinical compound library","volume":"6","author":"Niu","year":"2017","journal-title":"Emerg. Microbes Infect."},{"issue":"2","key":"10.1016\/j.bioorg.2022.106264_b0280","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1021\/acschemneuro.7b00349","article-title":"Identification of FDA-Approved Small Molecules Capable of Disrupting the Calmodulin-Adenylyl Cyclase 8 Interaction through Direct Binding to Calmodulin","volume":"9","author":"Hayes","year":"2018","journal-title":"ACS Chem. Neurosci."},{"issue":"24","key":"10.1016\/j.bioorg.2022.106264_b0285","doi-asserted-by":"crossref","first-page":"10257","DOI":"10.1021\/jm501100b","article-title":"Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals","volume":"57","author":"Vitaku","year":"2014","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2022.106264_b0290","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3390\/pathogens10020253","article-title":"YM155 Inhibits NleB and SseK Arginine Glycosyltransferase Activity","volume":"10","author":"Zhu","year":"2021","journal-title":"Pathogens"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822006708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822006708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:39:12Z","timestamp":1758616752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206822006708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":58,"alternative-id":["S0045206822006708"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.106264","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.106264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106264"}}